fda warning letters glp-1 september 2025 news FDA Warning Letter Breakdown: Sterility Failures, Subpotent GLP-1 Drugs, and a Compounding Pharmacy Operating Without Control

Thinking about buying GLP-1 and other products labeled “for research purposes” or “not for human consumption”? Think again. These products have not been reviewed by FDA for safety, effectiveness or quality and

21.68

★★★★☆4.8 (126)

Thinking about buying GLP-1 and other products labeled “for research purposes” or “not for human consumption”? Think again. These products have not been reviewed by FDA for safety, effectiveness or

25.24

★★★★★4.9 (98)

The FDA has issued a warning to Novo Nordisk over its alleged failure to report adverse side effects, including death, in patients who took its GLP-1 medications, popularly known as Ozempic and

22.13

★★★★★5.0 (157)

The FDA sent a warning letter to the maker of Ozempic and Wegovy over unreported potential GLP-1 side effects. Here's what to know

23.79

★★★★★4.7 (84)

FDA Issues 30 Warning Letters to Telehealth Firms Over Misleading Compounded GLP-1 Marketing

26.32

★★★★★4.9 (203)

September 15, 2025: Telehealth company must stop implying its compounded GLP -1 is FDA-approved, warns FDA – Partnership for Safe Medicines

22.86

★★★★★5.0 (176)

FDA Drug Recalls and Warnings: Illegal GLP-1 Sales and Misleading Marketing by Novo Nordisk and Eli Lilly

24.18

★★★★★4.8 (132)